Key Takeaways
The earnings improvement at pharma-biotech companies in the second quarter came from two fundamentally different kinds of money. One is the upfront payment and milestones from technology out-licensing deals; the other is actual sales growth from new drugs and biosimilars. The former tends to be recognized as one large amount at the moment a contract is signed, while the latter is recurring revenue that builds up quarter after quarter. Without distinguishing between the two, it's impossible to gauge whether this quarter's strong earnings will carry over into the next.
What Happened
According to a Yonhap News report, major domestic pharma-biotech companies posted improved earnings across the board in the second quarter of this year, driven by technology out-licensing achievements and expanded sales of new drugs and biosimilars. Read at face value, the press releases make it sound as though years of accumulated R&D pipelines suddenly bore commercial fruit all at once — but breaking earnings down by component reveals a clear difference in nature.
Technology out-licensing deals are typically structured in three stages: an upfront payment received when the contract is signed, milestone payments made each time a clinical or regulatory hurdle is cleared, and sales royalties once the drug is commercialized. Of these, the item usually recognized immediately and in the largest amount is the upfront payment. Royalties, by contrast, only materialize once the drug is actually being sold in overseas markets. Biosimilar revenue, meanwhile, is fundamentally different in character — it accumulates quarter after quarter as already-approved products are sold in the U.S. and European prescription markets.
Background and Context
Over the past several years, Korea's pharma-biotech industry has steadily increased the number of technology out-licensing deals signed with multinational drugmakers, while at the same time biosimilar latecomers have been expanding their share of the U.S. prescription market. This second quarter can be seen as a period in which both trends showed up in income statements at once, which on the surface makes it look like an industry-wide, across-the-board earnings beat.
Impact on the Market and Stocks (Tickers)
- Yuhan Corporation - With a track record of landmark technology out-licensing deals, its quarterly earnings volatility is largely driven by the timing of milestone and royalty recognition under its licensing agreements.
- Celltrion - Expanding U.S. prescriptions for its biosimilar lineup, including Remsima and Yuflyma, translates directly into recurring sales revenue rather than one-off contract payments.
- Samsung Biologics - As contract manufacturing (CDMO) orders increase, earnings improve simply from higher production-line utilization, independent of any technology out-licensing issues.
- SK Biopharmaceuticals - A case where growth in direct U.S. sales revenue from its in-house-developed new drug flows straight through to earnings.
- Alteogen - Because licensing-out deals for its proprietary platform technology are recognized as milestone revenue, how far each contract has progressed directly determines the sustainability of earnings.
Investor Checkpoints
- Check earnings disclosures item by item to determine whether technology out-licensing revenue is an upfront (one-off) payment or a royalty (recurring) stream.
- For biosimilar revenue, track sales volume together with average selling price (ASP) trends — only then can you distinguish a one-time bounce from genuine growth.
- Watch the schedule for the next clinical data readout and regulatory approval decisions, since milestone payments are only made once the corresponding stage is cleared.
- Assess the size of remaining milestones in technology out-licensing contracts together with the probability of commercialization success to gauge their future contribution to earnings.
Outlook
In the optimistic scenario, Korean biotech's technology out-licensing becomes not a one-off event but a pipeline that recurs every quarter. If so, this quarter's strong earnings mark the start of a trend. In the pessimistic scenario, this quarter's results may simply reflect a base effect from the upfront recognition of a specific deal. In that case, the next quarter would face a higher comparison base, creating a negative base-effect drag. There also remains the risk that scheduled milestones could be forfeited due to clinical trial failures or regulatory approval delays.
Yuhan Corporation: Real-Time Data Snapshot
Yuhan Corporation's latest closing price is 83,700 won (+1.45% from the previous session), and the composite signal combining foreign investor/institutional investor supply-demand (order flow) with news and momentum reads 🟡 Neutral / Wait-and-see. With positive and negative signals mixed, this is a stock to watch.
- ▲ Trend Alignment — Short- and medium-term uptrend alignment (1-day +1.4% · 1-week +3.8% · 1-month +20.4%)
※ Price and foreign/institutional investor supply-demand (order flow) data are provided by Korea Investment & Securities (KIS), as of the time of publication.
This article is content automatically summarized and analyzed based on the original news report. View original (Yonhap News Securities)
